Schneider LS - Search Results

1

Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria.

Franzen S, Smith JE, van den Berg E, Rivera Mindt M, van Bruchem-Visser RL, Abner EL, Schneider LS, Prins ND, Babulal GM, Papma JM. Franzen S, et al. Among authors: schneider ls. Alzheimers Dement. 2022 Apr;18(4):810-823. doi: 10.1002/alz.12433. Epub 2021 Sep 30. Alzheimers Dement. 2022. PMID: 34590409 Free PMC article. Review.

2

Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial.

Schneider LS, Ismail MS, Dagerman K, Davis S, Olin J, McManus D, Pfeiffer E, Ryan JM, Sultzer DL, Tariot PN. Schneider LS, et al. Schizophr Bull. 2003;29(1):57-72. doi: 10.1093/oxfordjournals.schbul.a006991. Schizophr Bull. 2003. PMID: 12908661

3

Drug development, clinical trials, cultural heterogeneity in Alzheimer disease: the need for pro-active recruitment.

Schneider LS. Schneider LS. Alzheimer Dis Assoc Disord. 2005 Oct-Dec;19(4):279-83. doi: 10.1097/01.wad.0000190808.97878.b8. Alzheimer Dis Assoc Disord. 2005. PMID: 16327360 Review.

4

A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type.

Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. Schneider LS, et al. Curr Alzheimer Res. 2005 Dec;2(5):541-51. doi: 10.2174/156720505774932287. Curr Alzheimer Res. 2005. PMID: 16375657 Clinical Trial.

5

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA; CATIE-AD Study Group. Schneider LS, et al. N Engl J Med. 2006 Oct 12;355(15):1525-38. doi: 10.1056/NEJMoa061240. N Engl J Med. 2006. PMID: 17035647 Free article. Clinical Trial.

6

Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer's disease?

Winstein CJ, Bentzen KR, Boyd L, Schneider LS. Winstein CJ, et al. Among authors: schneider ls. Curr Alzheimer Res. 2007 Jul;4(3):273-6. doi: 10.2174/156720507781077296. Curr Alzheimer Res. 2007. PMID: 17627484 Clinical Trial.

7

Prevention therapeutics of dementia.

Schneider LS. Schneider LS. Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S122-30. doi: 10.1016/j.jalz.2007.11.005. Epub 2007 Dec 21. Alzheimers Dement. 2008. PMID: 18631988 Review.

8

The perils of Alzheimer's drug development.

Schneider LS, Lahiri DK. Schneider LS, et al. Curr Alzheimer Res. 2009 Feb;6(1):77-8. doi: 10.2174/156720509787313871. Curr Alzheimer Res. 2009. PMID: 19199878 Free PMC article. No abstract available.

9

Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." A federally funded corporation for the prevention and treatment of cognitive impairment and brain aging.

Schneider LS. Schneider LS. Alzheimers Dement. 2009 Mar;5(2):172-9. doi: 10.1016/j.jalz.2009.01.023. Alzheimers Dement. 2009. PMID: 19328454 Review. No abstract available.

10

Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Wuthering forest plots: distinguishing the forest from the plots.

Schneider LS. Schneider LS. Alzheimers Dement. 2007 Jan;3(1):18-20. doi: 10.1016/j.jalz.2006.10.003. Alzheimers Dement. 2007. PMID: 19595911 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

621 results

Search Page